This Ares Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Turn Therapeutics Inc TTRX
$12.49
▼ -5.81%
($-0.77)
Open
$13.24
Prev Close
$13.26
Day Range
$12.30 – $13.68
52W Range
$2.57 – $26.50
Market Cap
$372.05M
Beta
0.42
EPS (TTM)
$-0.29
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2025-10-08 |
| Shares Out. | 29,790,000 |
| Website | turntherapeutics.com ↗ |
| Phone | 18185644011 |
| Employees | 2 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$5.8M |
| Free Cash Flow | -$4.2M |
| Total Assets | $17.0M |
| Total Liabilities | $16.3M |
| Equity | $686,888 |
About Turn Therapeutics Inc
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.
Turn Therapeutics Inc is a publicly traded company under the ticker symbol TTRX on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
8 analysts (2026-09-01)